Nektar Therapeutics (NKTR) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Howard W. Robin	Chief Executive Officer, President & Director	2.33M	1953
Linda Rubinstein	Chief Financial Officer and Principal Financial & Accounting Officer	460,850	1967
Sandra A. Gardiner	Interim Chief Financial Officer	686,400	1966
Jonathan Zalevsky	Senior Vice President and Chief Research & Development Officer	1.19M	1975
Ken Franke	Senior Vice President of Biologics Process Development & Manufacturing	0	N/A
Mary Tagliaferri	Chief Medical Officer	0	1966
Elizabeth Zhang	VP of Legal, Corporate Counsel & Secretary	0	N/A
Jennifer Ruddock	Chief Business Officer	0	N/A
Robert Bacci	Chief People Officer and Head of Quality & Facilities	0	N/A
Takahiro Miyazaki	Senior VP & Head of Research	0	N/A
Charleen Jue	Senior Vice President of Clinical Development Operations	0	N/A
Vivian Wu	Investor Relations	0	N/A
Jason Barnard	Chief Accounting Officer	0	N/A

Name

Title

Pay

Year Born

Howard W. Robin

Chief Executive Officer, President & Director

2.33M

1953

Linda Rubinstein

Chief Financial Officer and Principal Financial & Accounting Officer

460,850

1967

Sandra A. Gardiner

Interim Chief Financial Officer

686,400

1966

Jonathan Zalevsky

Senior Vice President and Chief Research & Development Officer

1.19M

1975

Ken Franke

Senior Vice President of Biologics Process Development & Manufacturing

N/A

Mary Tagliaferri

Chief Medical Officer

1966

Elizabeth Zhang

VP of Legal, Corporate Counsel & Secretary

N/A

Jennifer Ruddock

Chief Business Officer

N/A

Robert Bacci

Chief People Officer and Head of Quality & Facilities

N/A

Takahiro Miyazaki

Senior VP & Head of Research

N/A

Charleen Jue

Senior Vice President of Clinical Development Operations

N/A

Vivian Wu

Investor Relations

N/A

Jason Barnard

Chief Accounting Officer

N/A

Description

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.